It was reported last month that federal health officials are still conducting a months-long investigation into possible links between asthma drugs, including Merck’s Singulair, and suicide. In March, the Food and Drug Administration said it was reviewing a handful of reports involving mood changes, suicidal behavior and suicide in patients who had taken Singulair. But, over nine months later, the agency now says it still has not reached a conclusion and will continue its investigation of Singulair and similar drugs. First approved in 1998, Singulair was Merck’s best-selling product last year. The company expects to report between $4.3 and $4.5 billion in sales of the drug for 2008. It is part of a class of drugs that includes AstraZeneca PLC’s Accolate and Critical TherapeuticsInc.’s Zyflo.
Source: Associated Press
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.